William Rosenberg Professor of Medicine, Emeritus
Chabner BA, Johnson RE, Young RC, Canellos GP, Hubbard SP, Johnson SK, DeVita VT
Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Cancer. 1978 Aug; 42(2 Suppl):922-5.
Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma.
Philadelphia-chromosome-positive preleukaemic state. Lancet. 1972 Dec 09; 2(7789):1227-8.
Philadelphia-chromosome-positive preleukaemic state.
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood. 1974 Oct; 44(4):483-7.
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
Canellos GP, DeVita VT, Whang-Peng J, Carbone PP
Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood. 1971 Dec; 38(6):671-9.
Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia.
Anderson KC, Skarin AT, Rosenthal DS, MacIntyre JM, Pinkus GS, Case DC, Leonard RC, Canellos GP
Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Cancer Treat Rep. 1984 Nov; 68(11):1343-50.
Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
Lederman GS, Garnick MB, Canellos GP, Richie JP
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Chemotherapy of refractory germ cell cancer with Etoposide. J Clin Oncol. 1983 Nov; 1(11):706-9.
Chemotherapy of refractory germ cell cancer with Etoposide.
Pesando JM, Come SE, Stark J, Parker LM, Griffiths CT, Canellos GP
cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1147-8.
cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer.
Experimental approaches in the treatment of lymphoma. Baillieres Clin Haematol. 1987 Mar; 1(1):205-21.
Experimental approaches in the treatment of lymphoma.
Procabazine induced oxidative haemolysis: relationship in vivo red cell survival. Br J Haematol. 1974 Aug; 27(4):587-95.
Procabazine induced oxidative haemolysis: relationship in vivo red cell survival.
Young RC, Canellos GP, Chabner BA, Schein PS, Brereton HD, DeVita VT
Treatment of malignant melanoma with methyl CCNU. Clin Pharmacol Ther. 1974 Jun; 15(6):617-22.
Treatment of malignant melanoma with methyl CCNU.
Young RC, Walker MD, Canellos GP, Schein PS, Chabner BA, DeVita VT
Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU). Cancer. 1973 May; 31(5):1164-9.
Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU).
Hakami N, Neiman PE, Canellos GP, Lazerson J
Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med. 1971 Nov 18; 285(21):1163-70.
Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings.
Annals of oncology : official journal of the European Society for Medical Oncology
Current therapeutic strategies in Hodgkin's disease. Ann Oncol. 1992 Sep; 3 Suppl 4:67-8.
Current therapeutic strategies in Hodgkin's disease.
Wasserman TH, Petroni GR, Millard FE, Chung CT, Barcos M, Johnson JL, Canellos GP, Peterson BA
Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051). Cancer. 1999 Oct 15; 86(8):1590-5.
Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051).
Schein PS, Chabner BA, Canellos GP, Young RD, Berard C, DeVita VT
The British journal of cancer. Supplement
Results of combination chemotherapy of non-Hodgkin's lymphoma. Br J Cancer Suppl. 1975 Mar; 2:465-73.
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Tura S, Canellos G, Goldstone A, Longo D, McMillan A, Urba W, Zinzani PL
Hodgkin's disease: controversies and challenges for the future. Haematologica. 1991 Jul-Aug; 76(4):263-79.
Hodgkin's disease: controversies and challenges for the future.
Treatment of the non-Hodgkin's lymphomas. Med Times. 1978 Mar; 106(3):37-41.
Treatment of the non-Hodgkin's lymphomas.
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018 04 19; 378(16):1560.
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma.
Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009 Oct; 50(10):1606-17.
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
Soiffer RJ, Caligiuri MA, Tondini C, Canellos GP
High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. Cancer. 1989 Nov 15; 64(10):2014-8.
High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent.
Mentzer SJ, Osteen RT, Pappas TN, Rosenthal DS, Canellos GP, Wilson RE
Surgical therapy of localized abdominal non-Hodgkin's lymphomas. Surgery. 1988 Jun; 103(6):609-14.
Surgical therapy of localized abdominal non-Hodgkin's lymphomas.
Anderson KC, Ritz J, Takvorian T, Coral F, Daley H, Gorgone BC, Freedman AS, Canellos GP, Schlossman SF, Nadler LM
Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood. 1987 Feb; 69(2):597-604.
Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow.
Canellos GP, Mead JA, Greenberg NH, Schrecker AW
The effect of treatment with cytotoxic agents on mouse spleen dihydrofolate reductase activity. Cancer Res. 1967 Apr; 27(4):784-8.
The effect of treatment with cytotoxic agents on mouse spleen dihydrofolate reductase activity.
Hellman S, Chaffey JT, Rosenthal DS, Moloney WC, Canellos GP, Skarin AT
The place of radiation therapy in the treatment of non-Hodgkin's lymphomas. Cancer. 1977 Feb; 39(2 Suppl):843-51.
The place of radiation therapy in the treatment of non-Hodgkin's lymphomas.
Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP
Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980 Mar; 68(3):356-62.
Multimodality therapy for malignant mesothelioma based on a study of natural history.
Perloff M, Norton L, Korzun AH, Wood WC, Carey RW, Gottlieb A, Aust JC, Bank A, Silver RT, Saleh F, Canellos GP, Perry MC, Weiss RB, Holland JF
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May; 14(5):1589-98.
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Henderson IC, Hayes DF, Parker LM, Love S, Garber JE, Recht A, Breitmeyer JB, Harris JR, Canellos GP
Adjuvant systemic therapy for patients with node-negative tumors. Cancer. 1990 May 01; 65(9 Suppl):2132-47.
Adjuvant systemic therapy for patients with node-negative tumors.
Introduction to a special series of unique entities within the spectrum of large-cell lymphoma. Oncologist. 2006 Apr; 11(4):374.
Introduction to a special series of unique entities within the spectrum of large-cell lymphoma.
Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun; 18(6):1071-9.
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Basophilic chronic granulocytic leukaemia with hyperhistaminaemia. Br J Haematol. 1977 Jul; 36(3):367-72.
Basophilic chronic granulocytic leukaemia with hyperhistaminaemia.
Interferon in the treatment of malignant lymphoma. Semin Oncol. 1985 Dec; 12(4 Suppl 5):25-9.
Interferon in the treatment of malignant lymphoma.
Bagley CM, Canellos GP, Young RC, Gallelli JF, Devita VT
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemother Rep. 1972 Jun; 56(3):387-91.
Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously.
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov; 7(11):1630-6.
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.
Shapiro CL, Yeap BY, Godleski J, Jochelson MS, Shipp MA, Skarin AT, Canellos GP
Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Cancer. 1991 Aug 15; 68(4):699-705.
Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens.
The second chance for advanced Hodgkin's disease. J Clin Oncol. 1992 Feb; 10(2):175-7.
The second chance for advanced Hodgkin's disease.
Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20.
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
Hematology/oncology clinics of North America
Clinical characteristics of the blast phase of chronic granulocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):359-67.
Clinical characteristics of the blast phase of chronic granulocytic leukemia.
Mauch P, Larson D, Osteen R, Silver B, Yeap B, Canellos G, Weinstein H, Rosenthal D, Pinkus G, Jochelson M
Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol. 1990 Feb; 8(2):257-65.
Prognostic factors for positive surgical staging in patients with Hodgkin's disease.
Arseneau JC, Aamodt R, Johnston GS, Canellos GP
The Journal of laboratory and clinical medicine
Evidence for granulocytic incorporation of 67gallium in chronic granulocytic leukemia. J Lab Clin Med. 1974 Mar; 83(3):496-503.
Evidence for granulocytic incorporation of 67gallium in chronic granulocytic leukemia.
A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer. 1972 Dec; 30(6):1495-504.
A decade of combination chemotherapy of advanced Hodgkin's disease.
Anderson KC, Leonard RC, Canellos GP, Skarin AT, Kaplan WD
High-dose gallium imaging in lymphoma. Am J Med. 1983 Aug; 75(2):327-31.
Neumann CH, Robert NJ, Canellos G, Rosenthal D
Computed tomography of the abdomen and pelvis in non-Hodgkin lymphoma. J Comput Assist Tomogr. 1983 Oct; 7(5):846-50.
Computed tomography of the abdomen and pelvis in non-Hodgkin lymphoma.
Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei E, Henderson IC
Journal of the National Cancer Institute
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst. 1993 May 19; 85(10):812-7.
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P, Tarbell N, Coral F, Daley H, Yeap B
Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11; 316(24):1499-505.
Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis.
European journal of cancer & clinical oncology
The case for high-dose chemotherapy: is it chemotherapy's last gamble? Eur J Cancer Clin Oncol. 1987 Apr; 23(4):351-5.
The case for high-dose chemotherapy: is it chemotherapy's last gamble?
Karp DD, Parker LM, Binder N, Tantravahi R, Smith BR, Ervin TJ, Canellos GP
Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells. Am J Hematol. 1985 Mar; 18(3):243-9.
Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells.
Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr; 25(2 Suppl 2):58-65.
Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease.
Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8.
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
NCI monographs : a publication of the National Cancer Institute
Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma. NCI Monogr. 1987; (5):71-6.
Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
Young RC, Canellos GP, Chabner BA, Schein PS, Hubbard SP, DeVita VT
Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecol Oncol. 1974 Dec; 2(4):489-97.
Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide.
Canellos GP, Young RC, Berard CW, DeVita VT
Combination chemotherapy and survival in advanced Hodgkin's disease. Arch Intern Med. 1973 Mar; 131(3):388-90.
Combination chemotherapy and survival in advanced Hodgkin's disease.
Anderson KC, Garnick MB, Meshad MW, Cohen GI, Pegg WJ, Frei E, Israel M, Modest E, Canellos GP
Phase I trial of mitoxantrone by 24-hour continuous infusion. Cancer Treat Rep. 1983 May; 67(5):435-8.
Phase I trial of mitoxantrone by 24-hour continuous infusion.
Kornblith AB, Hollis DR, Zuckerman E, Lyss AP, Canellos GP, Cooper MR, Herndon JE, Phillips CA, Abrams J, Aisner J
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol. 1993 Nov; 11(11):2081-9.
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.
Henderson IC, Hayes DF, Come S, Harris JR, Canellos G
New agents and new medical treatments for advanced breast cancer. Semin Oncol. 1987 Mar; 14(1):34-64.
New agents and new medical treatments for advanced breast cancer.
Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G
The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol. 1985 May; 3(5):637-40.
The significance of the residual mediastinal mass in treated Hodgkin's disease.
Bagley CM, Young RC, Canellos GP, DeVita VT
Treatment of ovarian carcinoma: possibilities for progress. N Engl J Med. 1972 Oct 26; 287(17):856-62.
Treatment of ovarian carcinoma: possibilities for progress.
l-asparaginase resistance in human leukemia--asparagine synthetase. Biochem Pharmacol. 1969 Oct; 18(10):2578-80.
l-asparaginase resistance in human leukemia--asparagine synthetase.
Asparagine biosynthesis in human KB tumor cells: inhibitor studies with asparagine and glutamine antagonists. Cancer Res. 1970 Apr; 30(4):1081-3.
Asparagine biosynthesis in human KB tumor cells: inhibitor studies with asparagine and glutamine antagonists.
Griffin JD, Todd RF, Ritz J, Nadler LM, Canellos GP, Rosenthal D, Gallivan M, Beveridge RP, Weinstein H, Karp D, Schlossman SF
Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
Differentiation patterns in the blastic phase of chronic myeloid leukemia.
Griffin JD, Tantravahi R, Canellos GP, Wisch JS, Reinherz EL, Sherwood G, Beveridge RP, Daley JF, Lane H, Schlossman SF
T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood. 1983 Apr; 61(4):640-4.
T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia.
Kufe DW, Beardsley P, Karp D, Parker L, Rosowsky A, Canellos G, Frei E
High-dose thymidine infusions in patients with leukemia and lymphoma. Blood. 1980 Apr; 55(4):580-9.
High-dose thymidine infusions in patients with leukemia and lymphoma.
Phase II trial of combination methyl-GAG and vinblastine in the treatment of metastatic renal adenocarcinoma. Cancer Treat Rep. 1982 Jul; 66(7):1585-6.
Phase II trial of combination methyl-GAG and vinblastine in the treatment of metastatic renal adenocarcinoma.
Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC
Letter: Combination chemotherapy for breast cancer. Br Med J. 1975 Jan 04; 1(5948):37.
Letter: Combination chemotherapy for breast cancer.
Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 07; 299(23):1261-6.
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Mir R, Anderson J, Strauchen J, Nissen NI, Cooper MR, Rafla S, Canellos GP, Bloomfield CD, Gottlieb AJ, Peterson B
Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer. 1993 Mar 01; 71(5):1857-66.
Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B.
Systemic therapy of breast cancer. Med J Aust. 1988 Jan 18; 148(2):88-91.
Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR, Klatt M, Andersen J
Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol. 1989 Jul; 34(1):88-93.
Predictive factors for long-term survival in patients with advanced ovarian cancer.
Canellos GP, Sutliffe SB, DeVita VT, Lister TA
Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. Blood. 1979 May; 53(5):1014-7.
Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion.
Anderson KC, Nadler LM, Takvorian T, Freedman AS, Canellos GP, Schlossman SF, Ritz J
Monoclonal antibodies: their use in bone marrow transplantation. Prog Hematol. 1987; 15:137-81.
Monoclonal antibodies: their use in bone marrow transplantation.
Splenectomy for thrombocytopenia in chronic granulocytic leukemia. Cancer. 1972 Mar; 29(3):660-5.
Splenectomy for thrombocytopenia in chronic granulocytic leukemia.
Annals of the New York Academy of Sciences
Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci. 1974; 230:240-6.
Hypercalcemia in malignant lymphoma and leukemia.
Antman K, Pomfret E, Karp G, Skarin A, Canellos G
Phase II trial of etoposide in previously treated small cell carcinoma of the lung. Cancer Treat Rep. 1984 Nov; 68(11):1413-4.
Phase II trial of etoposide in previously treated small cell carcinoma of the lung.
Band PR, Canellos GP, Sears M, Israel L, Pocock SJ
Phase II trial with bleomycin, CCNU, and streptozotocin in patients with metastatic cancer of the breast. Cancer Treat Rep. 1977 Oct; 61(7):1365-7.
Phase II trial with bleomycin, CCNU, and streptozotocin in patients with metastatic cancer of the breast.
Neumann CH, Robert NJ, Rosenthal D, Canellos G
Clinical value of ultrasonography for the management of non-Hodgkin lymphoma patients as compared with abdominal computed tomography. J Comput Assist Tomogr. 1983 Aug; 7(4):666-9.
Clinical value of ultrasonography for the management of non-Hodgkin lymphoma patients as compared with abdominal computed tomography.
Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993 Apr 15; 71(8):2585-97.
Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.
Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy? Curr Hematol Malig Rep. 2011 Sep; 6(3):180-6.
Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy?
Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May; 97(5):758-65.
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Recent issues in chemotherapy for Hodgkin's disease. Curr Opin Oncol. 1989 Oct; 1(1):29-31.
Recent issues in chemotherapy for Hodgkin's disease.
Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012 Nov; 53(11):2143-50.
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Anderson KC, Kaplan WD, Leonard RC, Skarin AT, Canellos GP
Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma. Cancer Treat Rep. 1985 Dec; 69(12):1347-51.
Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma.
Costa JC, Rabson AS, Tralka TS, Engel WK, Canellos GP, Bratenahl CG
Letter: Leukaemia and lower-motor-neuron disease. Lancet. 1974 Jul 13; 2(7872):107-8.
Letter: Leukaemia and lower-motor-neuron disease.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
Studies of resistance to L-asparaginase in human leukemia. Recent Results Cancer Res. 1970; 33:188-93.
Studies of resistance to L-asparaginase in human leukemia.
L-asparaginase treatment of acute myeloblastic leukemia. Oncology. 1970; 24(5):349-57.
L-asparaginase treatment of acute myeloblastic leukemia.
Effects of sulphydryl inhibition on the erythrocyte in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1970 Mar; 18(3):269-77.
Effects of sulphydryl inhibition on the erythrocyte in paroxysmal nocturnal haemoglobinuria.
Kirkwood JM, Canellos GP, Ervin TJ, Pitman SW, Weichselbaum R, Miller D
Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen.
Blum RH, Corson JM, Wilson RE, Greenberger JS, Canellos GP, Frei E
Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD). Cancer. 1980 Oct 15; 46(8):1722-6.
Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD).
Ihde DC, Canellos GP, Schwartz JH, DeVita VT
Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients. Ann Intern Med. 1976 Jan; 84(1):17-21.
Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients.
Rosenthal S, Canellos GP, DeVita VT, Gralnick HR
Characteristics of blast crisis in chronic granulocytic leukemia. Blood. 1977 May; 49(5):705-14.
Characteristics of blast crisis in chronic granulocytic leukemia.
The cellular biology of the Reed-Sternberg cell. Blood. 1994 Aug 15; 84(4):1005-19.
The cellular biology of the Reed-Sternberg cell.
Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp MA, Kaplan WD, Tung N, Wheeler C, Beard CJ, Canellos GP
Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993 Jul; 11(7):1336-43.
Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients.
Robertson MJ, Tantravahi R, Griffin JD, Canellos GP, Cannistra SA
Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun; 43(2):95-102.
Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine.
Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN
High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1995 Dec; 13(12):2916-23.
High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Editorial: Combination chemotherapy for breast cancer. Cancer Chemother Rep. 1975 Sep-Oct; 59(5):893-4.
Editorial: Combination chemotherapy for breast cancer.
Sokal JE, Baccarani M, Tura S, Fiacchini M, Cervantes F, Rozman C, Gomez GA, Galton DA, Canellos GP, Braun TJ
Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985 Dec; 66(6):1352-7.
Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation.
Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR
Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol. 1985 Apr; 3(4):490-4.
Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival.
Canellos GP, De Vita VT, Schein P, Chabner B, Young RC
Proceedings: The chronic leukemias: current therapeutic concepts. Proc Natl Cancer Conf. 1972; 7:351-7.
Proceedings: The chronic leukemias: current therapeutic concepts.
DeVita VT, Arseneau JC, Sherins RJ, Canellos GP, Young RC
Intensive chemotherapy for Hodgkin's disease: long-term complications. Natl Cancer Inst Monogr. 1973 May; 36:447-54.
Intensive chemotherapy for Hodgkin's disease: long-term complications.
Oncologic emergencies. Semin Oncol. 1978 Jun; 5(2):225-7.
Ahles TA, Silberfarb PM, Rundle AC, Holland JC, Kornblith AB, Canellos GP, Green MR, Perry MC
Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B. Psychother Psychosom. 1994; 62(3-4):193-9.
Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B.
Schwartz JH, Canellos GP, Young RC, DeVita VT
Meningeal leukemia in the blastic phase of chronic granulocytic leukemia. Am J Med. 1975 Dec; 59(6):819-28.
Meningeal leukemia in the blastic phase of chronic granulocytic leukemia.
Budman DR, Anderson J, Obrecht JP, Canellos GP, Creaven P, Norton L, Gottlieb A
Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171. Cancer Treat Rep. 1985 Jun; 69(6):719-20.
Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171.
De Vita VT, Canellos GP, Schein PJ, Chabner BA, Bagley CM, Young RC
Proceedings: Malignant lymphoma: treatment with combination chemotherapy. Proc Natl Cancer Conf. 1972; 7:379-90.
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Rosenoff SH, Canellos GP, O'Connell M, Wiernik PH
Mediastinal adenopathy in granulocytic leukemia. Arch Intern Med. 1974 Jul; 134(1):135-8.
Mediastinal adenopathy in granulocytic leukemia.
Young RC, Canellos GP, Chabner BA, Hubbard SM, DeVita VT
Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 1978 Aug; 42(2 Suppl):1001-7.
Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy.
Therapy-related leukemia: a necessary complication of successful systemic chemotherapy? J Clin Oncol. 1984 Oct; 2(10):1077-9.
Therapy-related leukemia: a necessary complication of successful systemic chemotherapy?
Hubbard SM, Chabner BA, DeVita VT, Simon R, Berard CW, Jones RB, Garvin AJ, Canellos GP, Osborne CK, Young RC
Histologic progression in non-Hodgkin's lymphoma. Blood. 1982 Feb; 59(2):258-64.
Histologic progression in non-Hodgkin's lymphoma.
Schein PS, DeVita VT, Hubbard S, Chabner BA, Canellos GP, Berard C, Young RC
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med. 1976 Oct; 85(4):417-22.
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Asparaginase and leukaemia. Lancet. 1969 Mar 22; 1(7595):626.
Whang-Peng J, Canellos GP, Carbone PP, Tjio JH
Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood. 1968 Nov; 32(5):755-66.
Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML).
Canellos GP, Skarin AT, Rosenthal DS, Moloney WC, Frei E
Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. Cancer Treat Rep. 1981; 65 Suppl 1:125-9.
Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
Woolley PV, Osborne CK, Levi JA, Wiernik PH, Canellos GP
Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer. 1976 Aug; 38(2):1026-35.
Extranodal presentation of non-Hodgkin's lymphomas in the testis.
Antman KH, Blum RH, Wilson RE, Corson JM, Greenberger JS, Amato DA, Canellos GP, Frei E
Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control study. Cancer. 1983 Feb 01; 51(3):396-401.
Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control study.
Lampidis TJ, Henderson IC, Israel M, Canellos GP
Structural and functional effects of adriamycin on cardiac cells in vitro. Cancer Res. 1980 Nov; 40(11):3901-9.
Structural and functional effects of adriamycin on cardiac cells in vitro.
Arseneau JC, Canellos GP, Johnson R, DeVita VT
Risk of new cancers in patients with Hodgkin's disease. Cancer. 1977 Oct; 40(4 Suppl):1912-6.
Risk of new cancers in patients with Hodgkin's disease.
Canellos GP, Pocock SJ, Taylor SG, Sears ME, Klaasen DJ, Band PR
Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer. 1976 Nov; 38(5):1882-6.
Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard.
New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. J Clin Oncol. 2002 Feb 01; 20(3):607-9.
New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top.
Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. J Clin Oncol. 1991 Oct; 9(10):1916-20.
Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists.
Haskell CM, Canellos GP, Cooney DA, Hansen HH
Biocmical and pharmacologic effects of L-asparaginase in man. J Lab Clin Med. 1970 May; 75(5):763-70.
Biocmical and pharmacologic effects of L-asparaginase in man.
Hypoglycorrhachia in meningeal carcinomatosis. Cancer. 1966 May; 19(5):691-4.
Hypoglycorrhachia in meningeal carcinomatosis.
Balikian JP, Jochelson MS, Bauer KA, Skarkin AT, Garnick MB, Canellos GP, Smith EH
Pulmonary complications of chemotherapy regimens containing bleomycin. AJR Am J Roentgenol. 1982 Sep; 139(3):455-61.
Pulmonary complications of chemotherapy regimens containing bleomycin.
Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg. 1981 Apr; 54(4):455-60.
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.
The treatment of locally advanced breast cancer. J Clin Oncol. 1984 Mar; 2(3):149-51.
The treatment of locally advanced breast cancer.
Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Ann Intern Med. 1976 Aug; 85(2):149-54.
Mauch P, Leonard R, Skarin A, Rosenthal D, Come S, Chaffey J, Hellman S, Canellos G
Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol. 1985 Oct; 3(10):1301-8.
Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas.
Chemotherapy of advanced non-Hodgkin's lymphoma. Clin Haematol. 1979 Oct; 8(3):667-84.
Chemotherapy of advanced non-Hodgkin's lymphoma.
Diagnosis and treatment of Hodgkin's disease. Med Times. 1978 Mar; 106(3):30-5.
Diagnosis and treatment of Hodgkin's disease.
DeVita VT, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH, Frei E, Carbone PP, Canellos GP
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980 May; 92(5):587-95.
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute.
Mauch PM, Canellos GP, Shulman LN, Silver B, Tarbell NJ, Come S, Rabin MS, Coleman CN
Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. J Clin Oncol. 1995 Apr; 13(4):947-52.
Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial.
Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007 Jan; 48(1):97-103.
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
The role of alkylating agents in acute and chronic leukemia. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:46-7.
The role of alkylating agents in acute and chronic leukemia.
Rybak ME, Anderson JR, Poulin RF, Amrein PC, Canellos GP, Gottlieb AJ
Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972. Cancer Treat Rep. 1986 Oct; 70(10):1233-4.
Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972.
Treatment of the lymphomas. Semin Hematol. 1972 Apr; 9(2):193-209.
Schein PS, Chabner BA, Canellos GP, Young RC, Berard C, DeVita VT
Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. Blood. 1974 Feb; 43(2):181-9.
Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.
Bagley CM, Devita VT, Berard CW, Canellos GP
Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med. 1972 Feb; 76(2):227-34.
Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone.
Effect of chemotherapy and irradiation on interactions between stromal and hemopoietic cells in vitro. Scan Electron Microsc. 1982; (Pt 1):359-65.
Effect of chemotherapy and irradiation on interactions between stromal and hemopoietic cells in vitro.
Chabner BA, Johnson RE, DeVita VT, Canellos GP, Hubbard SP, Johnson SK, Young RC
Sequential staging in non-Hodgkin's lymphoma. Cancer Treat Rep. 1977 Sep; 61(6):993-7.
Sequential staging in non-Hodgkin's lymphoma.
Chronic granulocytic leukemia without the Philadelphia chromosome. Am J Clin Pathol. 1976 Apr; 65(4):467-70.
Chronic granulocytic leukemia without the Philadelphia chromosome.
Arseneau JC, Canellos GP, Banks PM, Berard CW, Gralnick HR, DeVita VT
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med. 1975 Mar; 58(3):314-21.
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival.
High-dose therapy: here to stay or just visiting? J Clin Oncol. 1994 Jan; 12(1):5-6.
High-dose therapy: here to stay or just visiting?
Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G
Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol. 1993 May; 11(5):937-42.
Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome.
Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, Bernhardt B, Duggan D, Faragher D, Schiffer C
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol. 1993 Jan; 11(1):155-60.
A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
Ihde DC, DeVita VT, Canellos GP, Young RC
Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. Blood. 1976 Feb; 47(2):211-22.
Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.
Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15; 21(4):607-14.
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Smith SM, Johnson JL, Niedzwiecki D, Eder JP, Canellos G, Cheson BD, Bartlett NL
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma. 2006 Aug; 47(8):1511-7.
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007 Jul; 48(7):1313-9.
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.
Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, Rosenthal DS, Skarin AT, Canellos GP
Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986 Jun; 104(6):757-65.
Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.
Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer. 1989 Mar 15; 63(6):1060-4.
Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease.
Garnick MB, Blum RH, Canellos GP, Mayer RJ, Parker L, Skarin AT, Li FP, Henderson IC, Frei E
Phase I trial of bruceantin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1929-32.
Arseneau JC, Bagley CM, Anderson T, Canellos GP
Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet. 1973 Jan 06; 1(7793):10-4.
Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma.
Young RC, DeVita VT, Serpick AA, Canellos GP
Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. N Engl J Med. 1971 Aug 26; 285(9):475-9.
Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
Canellos GP, Haskell CM, Arseneau J, Carbone PP
Hypoalbuminemic and hypocholesterolemic effect of L-asparaginase (NSC-109,229) treatment in man--a preliminary report. Cancer Chemother Rep. 1969 Feb; 53(1):67-9.
Hypoalbuminemic and hypocholesterolemic effect of L-asparaginase (NSC-109,229) treatment in man--a preliminary report.
Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP
Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med. 1983 Apr; 74(4):557-63.
Pulmonary complications associated with combination chemotherapy programs containing bleomycin.
Cunningham J, Mauch P, Rosenthal DS, Canellos GP
Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease. Cancer Treat Rep. 1982 Apr; 66(4):1015-22.
Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease.
Garnick MB, Canellos GP, Richie JP, Stark JJ
Sequential combination chemotherapy and surgery for disseminated testicular cancer: cis-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and adriamycin. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1681-6.
Sequential combination chemotherapy and surgery for disseminated testicular cancer: cis-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and adriamycin.
Antineoplastic Combined Chemotherapy Protocols
Anne E. Dyson Professor in Women's Cancers, Emeritus
Radiation Oncology Professor at Harvard Medical School, Emeritus
Joseph R. Bertino, Scientist and Clinical Oncologist. J Clin Oncol. 2022 05 10; 40(14):1511-1513.
Joseph R. Bertino, Scientist and Clinical Oncologist.
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT
Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014 Jan 20; 32(3):163-8.
Treatment of Hodgkin lymphoma: a 50-year perspective.
Advanced DLBCL: as systemic therapy improves, the need for RT diminishes. Oncology (Williston Park). 2014 Dec; 28(12):1085-6.
Advanced DLBCL: as systemic therapy improves, the need for RT diminishes.
Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Gianni Bonadonna: A Personal Remembrance. Oncologist. 2015 Nov; 20(11):1348-9.
Gianni Bonadonna: A Personal Remembrance.
Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna. Tumori. 2016 Mar-Apr; 102(2):124-6.
Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna.
Current strategies for early Hodgkin's disease. Ann Oncol. 1996; 7 Suppl 4:91-3.
Current strategies for early Hodgkin's disease.
Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA
Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol. 1997 Apr; 15(4):1631-7.
Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
Smith D, Shaffer K, Kirn D, Canellos GP, Mauch PM, Shulman LN
Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment. Oncology. 1998 Jul-Aug; 55(4):284-8.
Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment.
Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer. 2001 Jul 15; 92(2):207-17.
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Banks PM, Arseneau JC, Gralnick HR, Canellos GP, DeVita VT, Berard CW
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med. 1975 Mar; 58(3):322-9.
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations.
Will doxorubicin-containing regimens replace MOPP and its variants? Leukemia. 1991; 5 Suppl 1:50-2.
Will doxorubicin-containing regimens replace MOPP and its variants?
Griffin TW, Comis RL, Lokich JJ, Blum RH, Canellos GP
Phase I and preliminary phase II study of neocarzinostatin. Cancer Treat Rep. 1978 Dec; 62(12):2019-25.
Phase I and preliminary phase II study of neocarzinostatin.
A new addition to the Journal of Clinical Oncology: the art of oncology--when the tumor is not the target. J Clin Oncol. 2000 Jan; 18(1):3.
A new addition to the Journal of Clinical Oncology: the art of oncology--when the tumor is not the target.
Josting A, Engert A, Diehl V, Canellos GP
Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 1:112-6.
Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease.
Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003 Sep 01; 98(5):978-82.
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.
Wilson WH, Porcu P, Hurd D, Martin SE, Czuczman M, Niedzwiecki D, Saint Louis JD, Johnson JL, Cheson B, Canellos GP, Zelenetz AD
Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. J Clin Oncol. 2005 Jun; 23(16_suppl):6530.
Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103.
Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM
Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1997 Sep; 15(9):3060-6.
Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
Hughes-Davies L, Tarbell NJ, Coleman CN, Silver B, Shulman LN, Linggood R, Canellos GP, Mauch PM
International journal of radiation oncology, biology, physics
Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys. 1997 Sep 01; 39(2):361-9.
Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement.
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19; 327(21):1478-84.
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr; 17(4):1244.
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
The treatment of chronic granulocytic leukaemia. Clin Haematol. 1977 Feb; 6(1):113-28.
The treatment of chronic granulocytic leukaemia.
Domchek SM, Hecht JL, Fleming MD, Pinkus GS, Canellos GP
Lymphomas of the breast: primary and secondary involvement. Cancer. 2002 Jan 01; 94(1):6-13.
Lymphomas of the breast: primary and secondary involvement.
Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002 May 02; 346(18):1417-8.
Long-term follow-up of Hodgkin's disease trial.
Coiffier B, Shipp MA, Cabanillas F, Crowther D, Armitage JO, Canellos GP
Report of the first workshop on prognostic factors in large-cell lymphomas. Ann Oncol. 1991 Feb; 2 Suppl 2:213-7.
Report of the first workshop on prognostic factors in large-cell lymphomas.
Primary treatment of Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 4:153-8.
Canellos GP, Duggan D, Johnson J, Niedzwiecki D
How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004 Apr 15; 22(8):1532-3.
How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
Clinical cancer research : an official journal of the American Association for Cancer Research
The cancer and leukemia group B lymphoma committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3572s-5s.
The cancer and leukemia group B lymphoma committee.
Treatment of the leukemias. Med Times. 1978 Mar; 106(3):42-5, 49.
Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma? Ann Oncol. 1997; 8 Suppl 1:61-2.
Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma?
Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol. 1991 Jan; 2 Suppl 1:1-7.
Is there an effective salvage therapy for advanced Hodgkin's disease?
Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS, Rosenthal DS, Skarin AT, Canellos GP
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol. 1990 Jan; 8(1):84-93.
The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.
Weeks JC, Yeap BY, Canellos GP, Shipp MA
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991 Jul; 9(7):1196-203.
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission.
Griffin TW, Lister TA, Rybak ME, Rosenthal DS, Canellos GP, Woodruff R, Oliver KT
Treatment of acute nonlymphocytic leukemia with neocarzinostatin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1853-6.
Treatment of acute nonlymphocytic leukemia with neocarzinostatin.
Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol. 2012 Jun 20; 30(18):2171-2.
Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?
Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN
Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol. 2003 Feb; 14(2):268-72.
Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.
Relapsed and refractory Hodgkin's lymphoma: new avenues? Hematol Oncol Clin North Am. 2007 Oct; 21(5):929-41.
Relapsed and refractory Hodgkin's lymphoma: new avenues?
Kornblith AB, Herndon JE, Zuckerman E, Cella DF, Cherin E, Wolchok S, Weiss RB, Diehl LF, Henderson E, Cooper MR, Schiffer C, Canellos GP, Mayer RJ, Silver RT, Schilling A, Peterson BA, Greenberg D, Holland JC
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998 Mar; 9(3):297-306.
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.
Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Ann Oncol. 1998; 9 Suppl 5:S91-6.
Treatment of relapsed Hodgkin's disease: strategies and prognostic factors.
Kantoff PW, Kalish LA, McDowell-Bryant P, Canellos GP, Gibbs R, Richie JP, Garnick MB
Long-term followup of 150 patients with testicular cancer treated at a single institution. J Urol. 1992 Jan; 147(1):82-8.
Long-term followup of 150 patients with testicular cancer treated at a single institution.
Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, Henderson ES, Canellos GP, Kosty MP, Cooper MR
Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer. 1992 Nov 15; 70(10):2508-16.
Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD.
Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Semin Oncol. 1990 Feb; 17(1 Suppl 2):2-6.
Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Relapse with nodular lymphoma following combination chemotherapy for diffuse non-Hodgkin's lymphoma. Am J Clin Oncol. 1986 Oct; 9(5):420-3.
Relapse with nodular lymphoma following combination chemotherapy for diffuse non-Hodgkin's lymphoma.
Parker LM, Griffiths CT, Yankee RA, Knapp RC, Canellos GP
High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. Cancer Treat Rep. 1979 Feb; 63(2):275-9.
High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study.
The lymphomas. Semin Hematol. 1999 Oct; 36(4 Suppl 7):84-94.
Small non-cleaved cell lymphoma in adults. Am J Hematol. 1991 Sep; 38(1):40-7.
Small non-cleaved cell lymphoma in adults.
Shipp MA, Klatt MM, Yeap B, Jochelson MS, Mauch PM, Rosenthal DS, Skarin AT, Canellos GP
Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol. 1989 May; 7(5):613-8.
Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy.
Canellos GP, Abramson JS, Fisher DC, LaCasce AS
Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010 Mar 20; 28(9):1611-5.
Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.
Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
Reconstitution or resurrection of normal stem cells in chronic granulocytic leukemia. N Engl J Med. 1979 Feb 15; 300(7):360-1.
Reconstitution or resurrection of normal stem cells in chronic granulocytic leukemia.
Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988 Jun; 6(6):931-3.
Residual mass in lymphoma may not be residual disease.
LEES RS, CANELLOS GP, ROSENBERG IH, HATCH FT
Myocardial infarction in one of a pair of twenty-seven year old identical male twins. Am J Med. 1963 May; 34:741-6.
Myocardial infarction in one of a pair of twenty-seven year old identical male twins.
Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92.
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.
Gelrud LG, Arseneau JC, Milder MS, Kramer RJ, Swann SJ, Canellos GP, Johnston GS
The kinetics of 67gallium incorporation into inflammatory lesions: experimental and clinical studies. J Lab Clin Med. 1974 Mar; 83(3):489-95.
The kinetics of 67gallium incorporation into inflammatory lesions: experimental and clinical studies.
Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy. Am J Ophthalmol. 1969 Sep; 68(3):500-4.
Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy.
Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980 Mar; 68(3):370-6.
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity.
VP-16-213. A phase II trial using a weekly schedule. Cancer Clin Trials. 1981; 4(4):465-7.
VP-16-213. A phase II trial using a weekly schedule.
Canellos GP, Petroni GR, Barcos M, Duggan DB, Peterson BA
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol. 1995 Aug; 13(8):2005-11.
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
European journal of haematology. Supplementum
Clinical trials in North America. Eur J Haematol Suppl. 2005 Jul; (66):121-4.
Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. Semin Oncol. 1985 Sep; 12(3):281-8.
Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity.
L-asparaginase and Burkitt's lymphoma. Lancet. 1969 Aug 16; 2(7616):380.
Canellos GP, Devita VT, Gold GL, Chabner BA, Schein PS, Young RC
Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J. 1974 Feb 09; 1(5901):218-20.
Cyclical combination chemotherapy for advanced breast carcinoma.
Nadler LM, Takvorian T, Botnick L, Bast RC, Finberg R, Hellman S, Canellos GP, Schlossman SF
Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet. 1984 Aug 25; 2(8400):427-31.
Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma.
Cancer of the breast: the past decade (second of two parts). N Engl J Med. 1980 Jan 10; 302(2):78-90.
Cancer of the breast: the past decade (second of two parts).
Ervin TJ, Blum RH, Meshad MW, Kufe DW, Johnson RK, Canellos GP
Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1067-71.
Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Myelosuppression and "conventional" chemotherapy: what price, what benefit? J Clin Oncol. 1993 Jan; 11(1):1-2.
Myelosuppression and "conventional" chemotherapy: what price, what benefit?
Where does hematology end and oncology begin? Questions of professional boundaries and medical authority. J Clin Oncol. 2006 Jun 01; 24(16):2583-8.
Where does hematology end and oncology begin? Questions of professional boundaries and medical authority.
Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP
High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leuk Lymphoma. 2007 May; 48(5):870-80.
High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Canellos GP, Skarin AT, Klatt MM, Rosenthal DS, Case DC, Pinkus GS, Jochelson MS, Yeap BY, Shipp MA
The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol. 1987 Apr; 24(2 Suppl 1):2-7.
The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.
DeVita VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC
Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975 Feb 01; 1(7901):248-50.
Advanced diffuse histiocytic lymphoma, a potentially curable disease.
Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited. Oncology (Williston Park). 2012 Dec; 26(12):1199-200, 1202.
Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited.
The staging and treatment of non-Hodgkin's lymphoma. Br J Haematol. 1978 Aug; 39(4):477-82.
The staging and treatment of non-Hodgkin's lymphoma.
Letter: second malignancies complicating Hodgkin's disease in remission. Lancet. 1975 Jun 07; 1(7919):1294.
Letter: second malignancies complicating Hodgkin's disease in remission.
Young RC, Johnson RE, Canellos GP, Chabner BA, Brereton HD, Berard CW, DeVita VT
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep. 1977 Sep; 61(6):1153-9.
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Henderson IC, Gelman RS, Harris JR, Canellos GP
Duration of therapy in adjuvant chemotherapy trials. NCI Monogr. 1986; (1):95-8.
Duration of therapy in adjuvant chemotherapy trials.
Primack A, Wilson J, O'Connor GT, Engelman K, Hull E, Canellos GP
Hepatocellular carcinoma with the carcinoid syndrome. Cancer. 1971 May; 27(5):1182-9.
Hepatocellular carcinoma with the carcinoid syndrome.
Arseneau JC, Canellos GP, DeVita VT, Sherins RJ
Recently recognized complications of cancer chemotherapy. Ann N Y Acad Sci. 1974; 230:481-8.
Recently recognized complications of cancer chemotherapy.
High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma. Am J Med. 1984 Nov; 77(5):845-50.
High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma.
Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct; 69(4):585-94.
Dose: a critical factor in cancer chemotherapy.
Li FP, Corkery J, Canellos G, Neitlich HW
Breast cancer after Hodgkin's disease in two sisters. Cancer. 1981 Jan 01; 47(1):200-2.
Breast cancer after Hodgkin's disease in two sisters.
Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med. 1976 Apr; 84(4):389-92.
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol. 1997 Oct; 15(10):3169-70.
Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe?
Cameron CL, Cella D, Herndon JE, Kornblith AB, Zuckerman E, Henderson E, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Peterson BA, Holland JC
Health psychology : official journal of the Division of Health Psychology, American Psychological Association
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. Health Psychol. 2001 Jan; 20(1):71-5.
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning.
Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002 Apr 15; 20(8):2101-8.
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.
Who should pay for clinical research? J Clin Oncol. 1990 Nov; 8(11):1775-6.
Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option? Oncologist. 2009 Dec; 14(12):1167-8.
Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option?
Leopold KA, Canellos GP, Rosenthal D, Shulman LN, Weinstein H, Mauch P
Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol. 1989 Aug; 7(8):1059-65.
Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy.
Hematology in 2010: New therapies and standard of care in oncology. Nat Rev Clin Oncol. 2011 Feb; 8(2):67-8.
Hematology in 2010: New therapies and standard of care in oncology.
Young RC, Canellos GP, Chabner BA, Schein PS, DeVita VT
Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet. 1973 Jun 16; 1(7816):1339-43.
Maintenance chemotherapy for advanced Hodgkin's disease in remission.
Chabner BA, Canellos GP, Olweny CL, DeVita VT
Late recurrence of testicular tumor. N Engl J Med. 1972 Aug 24; 287(8):413.
Occasional notes. The management of early breast cancer. N Engl J Med. 1982 Jun 10; 306(23):1430-2.
Occasional notes. The management of early breast cancer.
Anderson T, DeVita VT, Simon RM, Berard CW, Canellos GP, Garvin AJ, Young RC
Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer. 1982 Dec 15; 50(12):2708-21.
Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute.
ASCO 30 years later: the state of the Society. J Clin Oncol. 1994 Nov; 12(11):2510-3.
ASCO 30 years later: the state of the Society.
Canellos GP, DeVita VT, Whang-Peng J, Chabner BA, Schein PS, Young RC
Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood. 1976 Jun; 47(6):1003-9.
Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.
Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma. Ann Oncol. 1994; 5 Suppl 2:121-2.
Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma.
Studies on the antitumor activity of gallium nitrate (NSC-15200) and other group IIIa metal salts. Cancer Chemother Rep. 1975 May-Jun; 59(3):599-610.
Studies on the antitumor activity of gallium nitrate (NSC-15200) and other group IIIa metal salts.
Shaffer K, Smith D, Kirn D, Kaplan W, Canellos G, Mauch P, Shulman LN
Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation. AJR Am J Roentgenol. 1996 Aug; 167(2):425-30.
Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation.
Clinical research saves money: reflections on high-dose therapy of breast cancer. J Clin Oncol. 1999 Jul; 17(7):1965-6.
Clinical research saves money: reflections on high-dose therapy of breast cancer.
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer. 1975 Jan; 35(1):98-110.
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer.
Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 01; 100(7):1438-48.
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
Clinical advances in hematology & oncology : H&O
Prognostic factors in large-cell lymphoma. Clin Adv Hematol Oncol. 2003 May; 1(5):269-70.
Prognostic factors in large-cell lymphoma.
Rosenthal S, Canellos GP, Whang-Peng J, Gralnick HR
Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. Am J Med. 1977 Oct; 63(4):542-7.
Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications.
Chemotherapy of the non-Hodgkin's lymphomas. Cancer. 1978 Aug; 42(2 Suppl):932-40.
Chemotherapy of the non-Hodgkin's lymphomas.
Bone marrow transplantation as salvage therapy in advanced Hodgkin's disease: allogeneic or autologous. J Clin Oncol. 1985 Nov; 3(11):1451-4.
Bone marrow transplantation as salvage therapy in advanced Hodgkin's disease: allogeneic or autologous.
Effect of L-asparaginase on mouse bone marrow, assayed by in vitro culture. Blood. 1970 Sep; 36(3):385-9.
Effect of L-asparaginase on mouse bone marrow, assayed by in vitro culture.
Blum RH, Wittenberg BK, Canellos GP, Mayer RJ, Skarin AT, Henderson IC, Parker LM, Frei E
A therapeutic trial of maytansine. Cancer Clin Trials. 1978; 1(2):113-7.
Chronic granulocytic leukemia. Med Clin North Am. 1976 Sep; 60(5):1001-18.
Abelson HT, Kufe DW, Skarin AT, Major P, Ensminger W, Beardsley GP, Canellos GP
Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:137-40.
Treatment of central nervous system tumors with methotrexate.
Todd RF, Garnick MB, Canellos GP, Richie JP, Gittes RF, Mayer RJ, Skarin AT
Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):17-20.
Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma.
Uematsu M, Tarbell NJ, Silver B, Coleman CN, Rosenthal DS, Shulman LN, Canellos G, Weinstein H, Mauch P
Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. Cancer. 1993 Jul 01; 72(1):207-12.
Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy.
Schein PS, Chabner BA, Canellos GP, Young RC, DeVita VT
Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. Cancer. 1975 Feb; 35(2):354-7.
Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy.
What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol. 2010 Jan 01; 28(1):e8.
What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma?
Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney W, Frei E, Canellos GP
High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977 Dec; 50(6):1039-47.
High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement.
Mauch P, Goffman T, Rosenthal DS, Canellos GP, Come SE, Hellman S
Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol. 1985 Sep; 3(9):1166-73.
Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone.
Haskell CM, Canellos GP, Cooney DA, Hardesty CT
Pharmacologic studies in man with crystallized L-asparaginase (NSC-109229). Cancer Chemother Rep. 1972 Oct; 56(5):611-4.
Pharmacologic studies in man with crystallized L-asparaginase (NSC-109229).
Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB, Serpick AA, Selawry OS
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969 Nov 06; 281(19):1028-34.
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.
Destructive bone lesions in chronic granulocytic leukemia. Medicine (Baltimore). 1969 Sep; 48(5):401-10.
Destructive bone lesions in chronic granulocytic leukemia.
Chemotherapy in the treatment of Hodgkin's disease. Semin Hematol. 1983 Jan; 20(1):1-24.
Chemotherapy in the treatment of Hodgkin's disease.
Cancer of the breast: the past decade (first of two parts). N Engl J Med. 1980 Jan 03; 302(1):17-30.
Cancer of the breast: the past decade (first of two parts).
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol. 1994 Apr; 45(4):283-7.
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan.
Marcus KC, Kalish LA, Coleman CN, Shulman LN, Rosenthal DS, Canellos GP, Mauch PM
Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy. J Clin Oncol. 1994 Dec; 12(12):2567-72.
Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ
Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996 May 01; 87(9):3625-32.
Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
Mentzer SJ, Osteen RT, Starnes HF, Moloney WC, Rosenthal D, Canellos G, Wilson RE
Splenic enlargement and hyperfunction as indications for splenectomy in chronic leukemia. Ann Surg. 1987 Jan; 205(1):13-7.
Splenic enlargement and hyperfunction as indications for splenectomy in chronic leukemia.
Pedrazzini A, Freedman AS, Andersen J, Heflin L, Anderson K, Takvorian T, Canellos GP, Whitman J, Coral F, Ritz J
Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood. 1989 Nov 01; 74(6):2203-11.
Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function.
Treatment of chronic granulocytic leukemia in blastic crisis. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:131-2.
Treatment of chronic granulocytic leukemia in blastic crisis.
The dose dilemma. J Clin Oncol. 1988 Sep; 6(9):1363-4.
Chabner BA, Sponzo R, Hubbard S, Canellos GP, Young RC, Schein PS, Devita VT
High-dose intermittent intravenous infusion of procarbazine (NSC-77213). Cancer Chemother Rep. 1973 Sep-Oct; 57(3):361-3.
High-dose intermittent intravenous infusion of procarbazine (NSC-77213).
Arseneau JC, Sponzo RW, Levin DL, Schnipper LE, Bonner H, Young RC, Canellos GP, Johnson RE, DeVita VT
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med. 1972 Nov 30; 287(22):1119-22.
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.
Hypercalcemia in chronic granulocytic leukemia. Cancer. 1971 Apr; 27(4):872-80.
Hypercalcemia in chronic granulocytic leukemia.
Skarin AT, Canellos GP, Rosenthal DS, Case DC, MacIntyre JM, Pinkus GS, Moloney WC, Frei E
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983 Feb; 1(2):91-8.
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).
Lipton JM, Nadler LM, Canellos GP, Kudisch M, Reiss CS, Nathan DG
Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest. 1983 Aug; 72(2):694-706.
Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man.
Henderson IC, Gelman R, Canellos GP, Frei E
Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep. 1981; 65 Suppl 1:67-75.
Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue.
Jacobs A, Slater A, Whittaker JA, Canellos G, Wiernik PH
Serum ferritin concentration in untreated Hodgkin's disease. Br J Cancer. 1976 Aug; 34(2):162-6.
Serum ferritin concentration in untreated Hodgkin's disease.
Healey EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K, Shulman LN, Coleman CN, Canellos G, Weinstein H
Prognostic factors for patients with Hodgkin disease in first relapse. Cancer. 1993 Apr 15; 71(8):2613-20.
Prognostic factors for patients with Hodgkin disease in first relapse.
Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011 Apr; 22(4):910-915.
End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.
Hormonal agents and treatment of cancer. Urology. 1986 Jan; 27(1 Suppl):4-8.
Hormonal agents and treatment of cancer.
Mauch P, Tarbell N, Weinstein H, Silver B, Goffman T, Osteen R, Zajac A, Coleman CN, Canellos G, Rosenthal D
Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol. 1988 Oct; 6(10):1576-83.
Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation.
Kaplan WD, Jochelson MS, Herman TS, Nadler LM, Stomper PC, Takvorian T, Andersen JW, Canellos GP
Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol. 1990 Dec; 8(12):1966-70.
Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma.
What constitutes "improved prognosis"? J Clin Oncol. 2008 Apr 20; 26(12):1913-4.
Antman KH, Skarin AT, Mayer RJ, Hargreaves HK, Canellos GP
Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore). 1979 Sep; 58(5):377-84.
Microangiopathic hemolytic anemia and cancer: a review.
Mauch PM, Canellos GP, Rosenthal DS, Hellman S
Reduction of fatal complications from combined modality therapy in Hodgkin's disease. J Clin Oncol. 1985 Apr; 3(4):501-5.
Reduction of fatal complications from combined modality therapy in Hodgkin's disease.
Johnson RE, Canellos GP, Young RC, Chabner BA, DeVita VT
Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Cancer Treat Rep. 1978 Mar; 62(3):321-5.
Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma.
Canellos GP, Whang-Peng J, Schnipper L, Brown CH
Prolonged cytogenetic and hematologic remission of blastic transformation in chronic granulocytic leukemia. Cancer. 1972 Jul; 30(1):288-93.
Prolonged cytogenetic and hematologic remission of blastic transformation in chronic granulocytic leukemia.
Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Serpick AA, Hansen HH
L-asparaginase toxicity. Cancer Res. 1969 Apr; 29(4):974-5.
Stahel RA, Takvorian RW, Skarin AT, Canellos GP
Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol. 1984 Oct; 20(10):1233-8.
Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature.
Takvorian T, Parker LM, Hochberg FH, Canellos GP
Autologous bone-marrow transplantation: host effects of high-dose BCNU. J Clin Oncol. 1983 Oct; 1(10):610-20.
Autologous bone-marrow transplantation: host effects of high-dose BCNU.
Young RC, Chabner BA, Hubbard SP, Canellos GP, DeVita VT
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. Natl Cancer Inst Monogr. 1975 Oct; 42:145-8.
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
Canellos GP, Young RC, Neiman PE, DeVita VT
Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Blood. 1975 Feb; 45(2):197-203.
Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.
Canellos GP, DeVita VT, Young RC, Chabner BA, Schein PS, Johnson RE
Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. Br J Cancer Suppl. 1975 Mar; 2:474-80.
Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.
Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? Leukemia. 1996 Jun; 10 Suppl 2:s68.
Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009 Dec 10; 361(24):2390-1.
Long-term follow-up of survival in Hodgkin's lymphoma.
CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. J Clin Oncol. 1997 May; 15(5):1713-6.
CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma.
Levine EG, Cirrincione CT, Szatrowski TP, Canellos G, Norton L, Henderson IC
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol. 1999 Jun; 22(3):218-22.
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.
Penson RT, Dignan FL, Canellos GP, Picard CL, Lynch TJ
Burnout: caring for the caregivers. Oncologist. 2000; 5(5):425-34.
Johnson EA, Klimstra DS, Herndon JE, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR
Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20(5-6):686-92.
Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.
Lymphoma: present and future challenges. Semin Hematol. 2004 Oct; 41(4 Suppl 7):26-31.
Lymphoma: present and future challenges.
Ernst TJ, Rosenthal DS, Griffin JD, Canellos GP
Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol. 1988 Dec; 11(6):623-6.
Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside.
Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol. 2005 Jul 20; 23(21):4574-6.
Chemotherapy alone for early Hodgkin's lymphoma: an emerging option.
Has the MOPP era ended? Br J Cancer. 1991 Apr; 63(4):483.
Canellos GP, Arseneau JC, DeVita VT, Whang-Peng J, Johnson RE
Second malignancies complicating Hodgkin's disease in remission. Lancet. 1975 Apr 26; 1(7913):947-9.
Second malignancies complicating Hodgkin's disease in remission.
Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E
Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep. 1979 May; 63(5):919-23.
Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog.
Hubbard SP, Chabner BA, Canellos GP, Young RC, DeVita VT
High dose intravenous bleomycin in the treatment of advanced lymphomas. Eur J Cancer (1965). 1975 Sep; 11(9):623-6.
High dose intravenous bleomycin in the treatment of advanced lymphomas.
Treatment and surgical staging of testicular and primary extragonadal germ cell cancer. JAMA. 1983 Oct 07; 250(13):1733-41.
Treatment and surgical staging of testicular and primary extragonadal germ cell cancer.
Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer. 1980 Apr 01; 45(7):1556-7.
Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate.
Parker LM, Griffiths CT, Yankee RA, Canellos GP, Gelman R, Knapp RC, Richman CM, Tobias JS, Weiner RS, Frei E
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer. 1980 Aug 15; 46(4):669-74.
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma.
Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, Silver B, Weinstein H, Come S, Canellos GP, Coleman CN
The cancer journal from Scientific American
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995 May-Jun; 1(1):33-42.
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.